Vaccine delivery in the skin

MyLife Technologies specializes in ceramic Micro Needle Arrays for intradermal vaccine delivery.

We offer major benefits for vaccine developers.

  • Delivering vaccines in the skin can reduce the amount of antigens by factors 3 to 20 less antigen for the same immunological respons as compared to intramuscular or sub-cutaneous injections. That makes a big difference in rapid response to new outbreaks of infectious diseases, at local, regional or global scale. 
  • Our cermic nano-pore micro needles enable the development of dry-products for self-administration and ambient storage and shipping.

 

Initial in vivo studies showed effective results using Influenza-A Spike Protein immunization and 100% survival in challenge studies with the 2009 pandemic Influenza virus H1N1 ('Mexican flu'), and on effective immunization against Diphtheria and Tetanus.

 

MyLife has demonstrated effective and efficient delivery a of a wide range of API's (Small Molecule Drugs, Peptides, Proteins) and vaccines, ranging in size from 100D to multi-valent sub-unit vaccines. In vivo models used in the past range from mice to mini-pigs.

 

First-in-Human projects conducted with the Center for Human Drug Research (CHDR - Leiden, NL) showed safety and tolerablity with and without the loaded peptide pharmaceutical. 

 

Current projects involve intradermal vaccine delivery of the SARS-CoV-2 Spike Protein, mRNA nano-particle delivery and HPV-antigen.  

 

Contact us for more details on the benefits for Vaccine developers.